Background {#Sec1}
==========

Frontotemporal dementia (FTD) is a neurodegenerative disease characterized clinically by changes in behaviour or language. Up to one-third of cases are caused by mutations in one of three major causal genes identified so far: microtubule-associated protein tau (*MAPT*), progranulin (*GRN*) and chromosome 9 open reading frame 72 (*C9ORF72*) \[[@CR1]--[@CR3]\].

Structural neuroimaging is recommended as part of the clinical evaluation in all patients with suspected dementia and forms part of the diagnostic criteria of FTD \[[@CR4], [@CR5]\]. Previous studies have shown that each mutation has a distinct pattern of atrophy: Mutations in *MAPT* have been associated with atrophy predominantly in the anteromedial temporal lobes \[[@CR6], [@CR7]\], whereas mutations in *GRN* are associated with an asymmetric pattern of atrophy that involves the frontal, temporal and parietal lobes \[[@CR6], [@CR8]\]; *C9ORF72* mutation carriers have relatively widespread cortical atrophy, including posterior areas \[[@CR1], [@CR9], [@CR10]\]. However, such studies have relied on volumetric ROIs or voxel-wise analyses that are difficult to translate into routine clinical practice, where visual evaluation remains the primary diagnostic method \[[@CR11]\].

To provide reliable identification and interpretation of imaging findings, different visual rating scales have been developed over time (*see* \[[@CR12]\] for a review). Recently, in a multi-centre pathologically confirmed series, we have shown that visual rating scales can improve the accuracy of clinical diagnosis of different dementias \[[@CR13]\]. However, only one study of visual rating scales has investigated the genetic forms of FTD so far \[[@CR14]\], and only in symptomatic patients in one genetic subtype, *C9ORF72*. The objective of the present study was therefore to determine specific visual patterns of atrophy in genetic FTD, in both symptomatic and presymptomatic mutation carriers, and in all three of the major genetic forms: *GRN*, *MAPT* and *C9ORF72*.

Methods {#Sec2}
=======

Participants {#Sec3}
------------

Subjects were recruited from the Genetic Frontotemporal Dementia Initiative (GENFI) study, which in the first phase consisted of 13 centres in the United Kingdom, Canada, Italy, The Netherlands, Sweden and Portugal. We included participants who were either known carriers of a pathogenic mutation in *MAPT*, *GRN* or *C9ORF72,* or family members at risk of carrying a mutation. In the at-risk group, those who had positive genetic testing were included in the pre-symptomatic group, and those that had negative genetic testing were included in the control group. In this way control subjects shared a similar environmental background but differed from carriers only for the absence of a pathogenic mutation in *MAPT*, *GRN* or *C9ORF72*. Participants were genotyped at their local site. Between January 2012 and April 2015, we enrolled 365 subjects, 343 of whom had a usable volumetric T1-weighted magnetic resonance imaging (MRI) scan. Local ethics committees at each site approved the study, and all participants provided written informed consent at enrolment.

Procedures {#Sec4}
----------

All participants underwent a standardized clinical assessment and a full neuropsychological battery (for details, *see* Rohrer et al., 2015 \[[@CR3]\]). Participants were scanned at their local site on scanners from three different manufacturers (Philips Healthcare, GE Healthcare Life Sciences, Siemens Healthcare Diagnostics). Magnetic field strength was 3 T for 295 scans (86%) and 1.5 T for 48 scans (14%). The protocol, designed to match across scanners as much as possible, included a volumetric T1-weighted MRI scan.

Visual rating scales {#Sec5}
--------------------

A protocol of 6 visual rating scales was applied in the cohort by two raters (GGF and PB), blinded to all clinical and demographic information, after a training set of 15 scans that included 5 cases with a clinical diagnosis of behavioural variant FTD, 5 with primary progressive aphasia and 5 control subjects. The training set was not included in the main analysis. The protocol made use of previously validated scales with particular attention to areas known to show atrophy in FTD \[[@CR13]\]. The following scales were chosen: orbitofrontal (OF), anterior cingulate (AC), frontoinsula (FI), anterior temporal (AT), medial temporal (MTA) and posterior (PA). With the OF, AC and FI scales, we looked at the widening of a single sulcus. Raters looked at the olfactory sulcus for the OF region, the anterior part of cingulate sulcus for AC region and the circular sulcus for the FI region. For all three scales, a four-part grading system was used: grade 0, representing no atrophy (no cerebrospinal fluid \[CSF\] visible within the sulcus); grade 1, mild widening of the sulcus (CSF just becomes visible); grade 2, moderate widening; and grade 3, severe widening (with the sulcus assuming a triangular shape). In order to ensure that the same areas were being reviewed on each scan, specific anatomical landmarks were used. The olfactory and cingulate sulci were reviewed in the coronal plane on the most anterior slice in which the corpus callosum was visible, whilst the circular sulcus was assessed also in the coronal plane, on the most anterior slice in which the anterior commissure was visible, as well as the two slices immediately posterior to this \[[@CR13]\]. The AT scale looked at the aspect of the temporal pole in coronal view, using a 5-point system: grade 0 representing normal appearances, grade 1 only slight prominence of anterior temporal sulci, grade 2 definite widening of the temporal sulci, grade 3 severe atrophy and ribbon-like nature of the gyri, and grade 4 a simple linear profile of the temporal pole \[[@CR15], [@CR16]\]. The MTA is a 5-point graded scale that looks at the medial temporal lobe in coronal view: grade 0 is normal; grade 1 a widened choroidal fissure; grade 2 an increased widening of the choroidal fissure, widening of temporal horn and opening of other sulci; grade 3 pronounced volume loss of the hippocampus; and grade 4 end-stage atrophy \[[@CR17]\]. The last scale used was PA, a 4-point scale evaluating posterior cortical atrophy using three views (coronal, axial and sagittal): grade 0 representing closed posterior cingulate and parieto-occipital sulci; grade 1 mild widening of the posterior cingulate and parieto-occipital sulci, with mild atrophy of the parietal lobes and precuneus; grade 2 substantial widening of the posterior cingulate and parieto-occipital sulcus, with substantial atrophy of the parietal lobes and precuneus; and grade 3 end-stage atrophy with evident widening of both sulci and knife-blade atrophy of the parietal lobes and precuneus \[[@CR18]\].

The software used for the visualization of the images was MRIcron \[[@CR19]\]. Images were rated in native space, in keeping with standard clinical reads. To aid rating consistency, reference images for each scale were provided to the raters. Right and left sides were assessed separately. The mean score of the two raters for each subject was calculated by averaging a combined right- and left-sided score in each rating scale. An asymmetry index was calculated as the sum of the absolute differences between the two sides for each scale. The raters re-rated a subset of 35 subjects randomly chosen in the main group to calculate intra-rater reliability.

To explore the relationship between each rating scale and the pattern of grey matter (GM) density, voxel-based morphometric analysis was performed using Statistical Parametric Mapping 12 \[[@CR12]\]. T1-weighted images were normalized and segmented into GM, white matter and CSF probability maps by using standard procedures and the fast-diffeomorphic image registration (DARTEL) algorithm \[[@CR20]\]. GM segments were affine-transformed into the MNI (Montreal Neurological Institute) space, modulated and smoothed using a Gaussian kernel with 6-mm FWHM before analysis. The GM tissue maps were fitted to a multiple regression model to identify the correlations with the six rating scales (OF, AC, FI, AT, MTA, PA). Age, sex and total intracranial volume were entered as covariates. The family-wise error rate for multiple comparisons correction was set at 0.05.

Statistical analysis {#Sec6}
--------------------

All the statistical analyses were performed using IBM SPSS Statistics version 22 for Windows software (IBM, Armonk, NY, USA). Differences in age and education were assessed with the *t* test, and differences in sex were evaluated with the χ^2^ test. Differences in the visual rating scale scores between groups were assessed using the Mann-Whitney *U* test. Inter- and Intra-rater reliability of each rating scale was determined using a two-way random, absolute, single-measure intra-class correlation coefficient (ICC).

Results {#Sec7}
=======

Demographics {#Sec8}
------------

The cohort consisted of 343 subjects, including 132 presymptomatic and 63 symptomatic individuals as well as 148 control subjects (*see* Table [1](#Tab1){ref-type="table"}). Symptomatic subjects were older than control subjects, independently of the mutation status. Moreover, the *MAPT* symptomatic carriers were younger than *GRN* and *C9ORF72* symptomatic carriers, as were *MAPT* presymptomatic carriers compared with the other two groups of asymptomatic carriers. Regarding sex, symptomatic *MAPT* and *C9ORF72* carriers were significantly different (*p* \< 0.05) from control subjects and *GRN* symptomatic carriers.Table 1Demographic data and visual rating scoresControl subjects*GRNC9ORF72MAPT*Total*GRNC9ORF72MAPT*TotalSignificancePresymptomaticSymptomaticNumber14866422413217311563Age48.86 (14.32)49.55 (10.90)44.66 (11.49)38.70 (8.80)46.02 (11.42)63.96 (5.70)65.92 (7.61)57.17 (8.21)63.31 (8.02)^a^\*^,b^\*^,c^\*^,d,e,g^\*Sex90 M41 M25 M14 M80 M11 M9 M4 M24 M^c,d,e,f^58 F25 F17 F10 F52 F6 F22 F11 F39 FOF0.19 (0.33)0.20 (0.35)0.33 (0.55)0.28 (0.70)0.26 (0.50)1.99 (0.55)1.54 (0.72)1.43 (0.70)1.63 (0.70)^b^\*^,c^\*^,d^\*^,e,f^AC0.35 (0.37)0.46 (0.49)0.45 (0.49)0.38 (0.65)0.44 (0.52)2.09 (0.69)1.65 (0.69)1.35 (0.52)1.69 (0.70)^b^\*^,c^\*^,d^\*^,f^AT0.22 (0.35)0.30 (0.38)0.30 (0.48)0.31 (0.72)0.30 (0.48)1.53 (0.57)1.44 (0.71)2.38 (0.93)1.69 (0.82)^b^\*^,c^\*^,d^\*^,f,g^FI0.61 (0.47)0.64 (0.47)0.66 (0.64)0.49 (0.55)0.62 (0.54)2.24 (0.42)2.10 (0.50)1.80 (0.52)2.07 (0.50)^b^\*^,c^\*^,d^\*^,f^MTA0.28 (0.41)0.31 (0.40)0.45 (0.74)0.51 (0.74)0.39 (0.60)1.40 (0.64)1.82 (1.10)2.60 (1.28)1.89 (1.12)^a,b^\*^,c^\*^,d^\*^,f^PA0.36 (0.52)0.33 (0.52)0.42 (0.59)0.18 (0.25)0.33 (0.51)1.79 (0.77)1.66 (0.72)0.77 (0.55)1.48 (0.80)^b^\*^,c^\*^,d,f^\*^,g^\*ASYMM1.49 (0.90)1.79 (1.20)1.62 (1.08)1.50 (0.92)1.68 (1.11)4.41 (2.00)2.92 (1.23)2.20 (0.88)3.15 (1.62)^b^\*^,c^\*^,d,e,f^\*^,g^*Abbreviations: GRN* Progranulin, *C9ORF72* Chromosome 9 open reading frame 72, *MAPT* Microtubule-associated protein tau, *OF* Orbitofrontal rating scale, *AC* Anterior cingulate rating scale, *AT* Anterior temporal rating scale, *FI* Frontoinsula rating scale, *MTA* Medial temporal atrophy rating scale, *PA* Posterior atrophy rating scale, *ASYMM* Asymmetry indexData are reported as mean (SD). The *t* test was used for age and education, the χ^2^ was used for sex, and the Mann-Whitney *U* test was used for visual rating scales^a^Controls vs Presymtomatic *MAPT*^b^Controls vs Symptomatic *GRN*^c^Controls vs Symptomatic *C9ORF72*^d^Controls vs Symptomatic *MAPT*^e^Symptomatic *GRN* vs Symptomatic *MAPT*^f^Symptomatic *GRN* vs Symptomatic *C9ORF72*^g^Symptomatic *C9ORF72* vs Symptomatic *MAPT*\* *P* \< 0.001; otherwise, *P* \< 0.05

Intra- and inter-rater reliability {#Sec9}
----------------------------------

All the scales demonstrated good inter-rater reliability (ICC \> 0.73) (*see* Table [2](#Tab2){ref-type="table"}), with the MTA scale performing best overall. Considering the intra-rater scores, rater 1 ICCs were greater than 0.82 for all the scales, whereas rater 2 had scores greater than 0.89 for all the scales.Table 2Intra and inter rater agreement scoresOFACATFIMTAPAInterraterRaters 1--20.820.740.770.750.880.73IntraraterRater 10.890.820.950.820.900.93Rater 20.970.900.960.910.960.89*Abbreviations: OF* Orbitofrontal rating scale, *AC* Anterior cingulate rating scale, *AT* Anterior temporal rating scale, *FI* Frontoinsula rating scale, *MTA* Medial temporal atrophy rating scale, *PA* Posterior atrophy rating scaleInter- and intra-rater agreement intraclass correlation coefficient score for each visual rating scale is shown

Mean visual rating scores {#Sec10}
-------------------------

All the scales and the asymmetric index were significantly higher in the three symptomatic groups than for the respective control subjects (Table [1](#Tab1){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"}). Symptomatic carriers of *MAPT* had higher scores in the AT region (2.38) than the other two groups (*GRN*, 1.53; *p* = 0.002; *C9ORF72*, 1.44; *p* = 0.001) and in the MTA scale (2.60) than *GRN* (1.40; *p* = 0.005), with a trend in comparison with *C9ORF72* (1.82; *p* = 0.061). By contrast, symptomatic carriers of *GRN* obtained higher scores in the OF scale (1.99) than the other two groups (*MAPT*, 1.43; *p* = 0.016; *C9ORF72*, 1.54; *p* = 0.043) and in the AC (2.09), FI (2.24), and PA (1.79) scales compared with *MAPT* (AC, 1.35; *p* = 0.004; FI, 1.80; *p* = 0.014; PA, 0.77; *p* \< 0.001) but not *C9ORF72*. *GRN* symptomatic carriers also showed the highest asymmetry index scores (4.41) compared with the other two groups (*C9ORF72*, 2.92; *p* = 0.009; *MAPT*, 2.20; *p* \< 0.001), with *C9ORF72* showing a significantly higher index than *MAPT* (*p* = 0.036). Symptomatic carriers of *C9ORF72* scored higher than *MAPT* only in the PA scale (*C9ORF72*, 1.66; *MAPT*, 0.77; *p* \< 0.001).Fig. 1Mean score of each visual rating scale in each group

In the presymptomatic group, *MAPT* carriers scored significantly higher than the control subjects in the MTA scale (*MAPT*, 0.51; CON, 0.28; *p* = 0.029) but not the other scales. No differences were found in the comparison of the other two presymptomatic groups (*GRN* and *C9ORF72*) with control subjects. There were also no differences between presymptomatic groups in terms of scores on the visual scales or on the asymmetry index.

Voxel-based morphometric analysis {#Sec11}
---------------------------------

The voxel-based morphometric analysis revealed a negative correlation of each visual rating scale score with an area of GM atrophy in the same (expected) region (*see* Fig. [2](#Fig2){ref-type="fig"}). No positive correlations were found.Fig. 2Representative coronal (for all scales except posterior atrophy scale) and sagittal (posterior atrophy scale) T1-weighted magnetic resonance images of symptomatic carriers of *GRN*, *MAPT*, and *C9ORF72* mutations (top three rows). Voxel-based morphometric analysis showing areas of significant negative correlation between the scales and grey matter. Maps showing z-scores were rendered on a study-specific template in MNI (Montreal Neurological Institute) space (bottom row). Images are shown with the left hemisphere on the left side of the figure

Discussion {#Sec12}
==========

Using simply applied visual rating scales, we have identified typical patterns of atrophy for each group of mutation carriers: anterior and medial temporal for *MAPT*, asymmetric frontal (orbitofrontal, cingulate, frontoinsular) and parietal for *GRN* and widespread for *C9ORF72* (*see* Fig. [2](#Fig2){ref-type="fig"}). This is consistent with previous studies on patients with genetic FTD using voxel-based morphometry \[[@CR6], [@CR9], [@CR10]\], even with the limitations of a semiquantitative assessment of atrophy. We also validated the visual rating scales using voxel-based morphometry, with each scale correlating with the specific brain region that the scale was designed to assess.

Only one previous study has investigated visual rating scales in genetic FTD: Devenney et al. used seven visual rating scales to describe the features of symptomatic *C9ORF72* carriers, but they did not find any statistical differences between *C9ORF72* and control subjects; they observed only a trend toward greater precuneus atrophy \[[@CR14]\].

It has recently been demonstrated that GM changes can be identified years before the expected onset of symptoms in adults at risk of genetic FTD \[[@CR3]\]. In particular, in individuals with *MAPT* mutations, atrophy was first noted in the hippocampus and amygdala, followed by the temporal lobe and later the insula; in *GRN* mutation carriers, differences started in the insula, followed by the temporal and parietal lobes and thereafter the striatum; in the *C9ORF72* group, changes were found very early in subcortical areas, the insula and the occipital cortex, then the frontal and temporal lobes and subsequently the cerebellum. This differential neuroanatomical involvement within the three genetic groups is likely to represent differently vulnerable large-scale neural networks, with pathological protein spread through those networks as the disease progresses. However, the underlying biology of this differential vulnerability is not yet understood. In our study, we demonstrated that presymptomatic *MAPT* carriers without symptoms had more medial temporal lobe atrophy than control subjects. However, we could not find any presymptomatic difference for individuals with *GRN* or *C9ORF72* mutations. There may be multiple reasons for this, including the nature of the cohort (with a number of cases far from expected onset), the pattern of atrophy (involvement of areas such as striatum, thalamus and cerebellum not identified by such scales), and the lack of sensitivity of the technique (which is likely to be more so for some regions than others).

Asymmetric atrophy is confirmed as one of the main features of *GRN* patients, but we could not find it in presymptomatic *GRN* carriers \[[@CR3]\], probably because the changes are mild and are seen just a few years before the onset of the disease, whereas in our study we considered the group of presymptomatic cases as a whole, without stratifying by expected age at onset. Unexpectedly, we found *C9ORF72* patients to be more asymmetric than *MAPT*, although less than *GRN*. This is in contrast to previous studies that showed a relatively symmetric atrophy in frontal, temporal and parietal lobes in *C9ORF72* patients \[[@CR9], [@CR21], [@CR22]\]. A possible explanation can be that visual rating scales measure sulcal opening, which can reflect not only the amount of cortical GM atrophy but also other factors, such as CSF or white matter, that can be different in *C9ORF72*. Nevertheless, our study's aim was to replicate real-life visual assessment of MRI scans using scanners of different types and field strengths and not requiring any expensive software or time-consuming post-processing techniques. The raters adopted a naturalistic approach, independently identifying the slices for the rating. This can result in rating different slices, but the scores obtained by the two raters in terms of intra- and inter-rater reliability are in line with the literature or better in the case of MTA \[[@CR23]\].

Conclusions {#Sec13}
===========

We have demonstrated differences among groups of mutations using a simple-to-use, reproducible and validated set of visual rating scales. Patterns of atrophy can be useful to help differentiate these groups and help predict the presence of a gene mutation in subjects with FTD. Clinicians can integrate the information obtained using MRI data with clinical features (e.g., psychosis in *C9ORF72*) and family history to tailor an approach to genetic testing \[[@CR9], [@CR14]\]. Further studies of visual rating scales of other important regions (such as subcortical areas) may add to our findings in improving differentiation between different mutations in FTD.
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We thank the participants and their families for taking part in the GENFI study.

Funding {#FPar1}
=======

This work was supported by grants from the Italian Ministry of Health and the Monzino Foundation (to ES). GGF was supported by Associazione Italiana Ricerca Alzheimer ONLUS (AIRAlzh Onlus)-COOP Italia. The Dementia Research Centre is supported by Alzheimer's Research UK, the Brain Research Trust, and The Wolfson Foundation. This work was supported by the National Institute for Health Research (NIHR) Queen Square Dementia Biomedical Research Unit, the NIHR University College London Hospitals NHS Foundation Trust Biomedical Research Centre and the Leonard Wolfson Experimental Neurology Centre (LWENC) Clinical Research Facility. This work was also supported by The Bluefield Project. This work was supported by the Medical Research Council (MRC) UK GENFI grant (MR/M023664/1). JDR is supported by an MRC Clinician Scientist Fellowship (MR/M008525/1) and has received funding from the NIHR Rare Diseases Translational Research Collaboration (BRC149/NS/MH).

Availability of data and materials {#FPar2}
==================================

The datasets generated and analysed during the present study are available from the corresponding author on reasonable request.

GGF designed the study, analysed and interpreted the data, and drafted the manuscript. PB, AA and MB analysed and interpreted the data. KMD, DMC, SH, MMe and CF analysed the data. AMP and LG made minor contributions to analysis of the data. JvS, BB, AdM, MMa, MCT, JBR, CG, FT, GBF, RL, EF, SS and ES collected data and revised the manuscript for intellectual content. JDR and DG drafted and revised the manuscript for intellectual content. All authors read and approved the final manuscript.

Ethics approval and consent to participate {#FPar3}
==========================================

Local ethics committees approved the study at each site, and all participants provided written informed consent.

Competing interests {#FPar4}
===================

The authors declare that they have no competing interests.

Publisher's Note {#FPar5}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
